Vanguard Group Inc Immuneering Corp Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Immuneering Corp stock. As of the latest transaction made, Vanguard Group Inc holds 1,203,666 shares of IMRX stock, worth $1.72 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,203,666

Previous 1,073,815 12.09%

Holding current value

$1.72 Million

Previous $7.89 Million 55.93%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$1.91 - $7.32 $248,015 - $950,509	129,851 Added 12.09%	1,203,666 $3.48 Million
Q4 2023 Feb 14, 2024	BUY	$4.84 - $8.44 $145,020 - $252,887	29,963 Added 2.87%	1,073,815 $7.89 Million
Q3 2023 Nov 14, 2023	BUY	$7.21 - $10.68 $308,025 - $456,270	42,722 Added 4.27%	1,043,852 $8.02 Million
Q2 2023 Aug 14, 2023	BUY	$6.49 - $13.36 $812,301 - $1.67 Million	125,162 Added 14.29%	1,001,130 $10.2 Million
Q1 2023 May 15, 2023	BUY	$3.78 - $10.38 $144,732 - $397,439	38,289 Added 4.57%	875,968 $8.51 Million

Q4 2022 Feb 10, 2023	BUY	$4.09 - $10.24 $78,487 - $196,505	19,190 Added 2.34%	837,679 $4.06 Million
Q3 2022 Nov 14, 2022	BUY	$5.0 - $12.85 $389,330 - $1 Million	77,866 Added 10.51%	818,489 $11.7 Million
Q2 2022 Aug 12, 2022	SELL	$3.89 - $7.81 $279,181 - $560,515	-71,769 Reduced 8.83%	740,623 $4.01 Million
Q1 2022 May 13, 2022	BUY	$6.47 - $16.99 $3.23 Million - $8.47 Million	498,479 Added 158.8%	812,392 $5.26 Million
Q4 2021 Feb 14, 2022	SELL	$16.12 - $31.02 $478,570 - $920,921	-29,688 Reduced 8.64%	313,913 $5.08 Million
Q3 2021 Nov 12, 2021	BUY	$17.0 - $32.84 $5.84 Million - $11.3 Million	343,601 New	343,601 $9.12 Million

Others Institutions Holding IMRX

# of Institutions

Shares Held

11.6M

Call Options Held

Put Options Held

View Full List

About Immuneering Corp

Ticker IMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,392,300
Market Cap $37.7M
Description
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...

More about IMRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Immuneering Corp Transaction History